Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
295 hedge funds and large institutions have $5.24B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2020 Q1 according to their latest regulatory filings, with 55 funds opening new positions, 98 increasing their positions, 114 reducing their positions, and 38 closing their positions.
45% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 38
21% more call options, than puts
Call options by funds: $14.2M | Put options by funds: $11.7M
6% more funds holding in top 10
Funds holding in top 10: 16 → 17 (+1)
5% more funds holding
Funds holding: 281 → 295 (+14)
14% less repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 114
16% less capital invested
Capital invested by funds: $6.22B → $5.24B (-$978M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$75.5M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
+$67.4M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$49.2M |
| 4 |
DM
Deerfield Management
New York
|
+$38.8M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
+$30.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
-$42.7M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$41.2M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$36.2M |
| 4 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
-$31.4M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$28.6M |
HZNP Hedge Fund Activity: Q1 2020 in Review
295 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q1 2020, worth a combined $5.24B — down 16% from $6.22B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new HZNP positions and 38 closed out — a net gain of 17 holders — while 98 added to existing stakes and 114 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $75.5M. The largest seller was Scopia Capital Management, cutting an estimated $42.7M.
- 295 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q1 2020, up from 281 in Q4 2019.
- Funds reported $5.24B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q1 2020, down 16% quarter-over-quarter.
- 55 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q1 2020 and 38 closed out, a net change of +17 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q1 2020 was Citadel Advisors, an estimated $75.5M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q1 2020 was Scopia Capital Management, an estimated $42.7M sold.
Based on aggregated 13F filings for Q1 2020.